Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-6: weekly eloralintide versus placebo in adults with persistent obesity or overweight on stable weekly incretin therapy
MOH_2026-02-04_015636Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eloralintide in obesity, Overweight and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
eloralintide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2026-02-04_015636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-04_015636.